Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.
Paradigm Biopharmaceuticals has reached 50% patient enrolment in its global PARA_OA_012 Phase 3 osteoarthritis trial, marking a key operational milestone as dosing of all participants required for the interim analysis dataset has commenced. The study aims to recruit 466 patients worldwide, comparing iPPS with placebo, with patient follow-up to Day 112 across sites in Australia, the U.S., Europe, and Asia.
The interim dataset will undergo cleaning and independent data monitoring committee statistical review after completion of Day 112 assessments, with results expected in August 2026. PARA_OA_012 closely mirrors the earlier PARA_OA_008 trial, which showed clinically meaningful improvements in pain and function, while incorporating methodological refinements to strengthen data quality and manage placebo response.
Key enhancements include using weekly averages of daily pain recordings as the primary pain endpoint to reduce recall bias and increase sensitivity in detecting treatment effects. WOMAC outcomes remain as secondary endpoints, and the protocol reflects learnings from prior studies and regulatory guidance, supporting Paradigm’s efforts to de-risk development and reinforce the robustness of its Phase 3 osteoarthritis program.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on discovering, developing, and delivering pharmaceutical therapies to improve patients’ health and quality of life. Its current lead program is injectable pentosan polysulfate sodium (iPPS) for osteoarthritis, targeting diseases where inflammation and tissue degeneration play a central pathogenic role.
YTD Price Performance: -25.00%
Average Trading Volume: 934,856
Technical Sentiment Signal: Sell
Current Market Cap: A$113.5M
For a thorough assessment of PAR stock, go to TipRanks’ Stock Analysis page.